

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vincent Medical Holdings Limited

永勝醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1612)

**VOLUNTARY ANNOUNCEMENT
UNAUDITED REVENUE PERFORMANCE
FOR THE THREE MONTHS AND NINE MONTHS ENDED
30 SEPTEMBER 2021**

This announcement is made by Vincent Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis with the purpose of allowing the investing public to understand the Group’s revenue performance for the three months and nine months ended 30 September 2021 (the “**Periods**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that based on the unaudited consolidated management accounts for the Periods, the Group’s revenue for the three months ended 30 September 2021 represents an increase of 22.1% as compared with the three months ended 30 June 2021, mainly attributable to the expanding sales of respiratory products in new geographical markets, growing imaging disposable products segment and the continuous recovery of the orthopaedic and rehabilitation products segment.

For the three months and nine months ended 30 September 2021, the Group’s revenue amounted to HK\$231.4 million and HK\$602.1 million respectively, representing a decrease of 42.0% and 33.2% respectively as compared to the corresponding periods in the previous year, primarily reflecting the lower sales of respiratory products.

The segmental revenue information by product category for the Periods is summarised as below:

	Three months ended 30 June (unaudited)			Three months ended 30 September (unaudited)			Nine months ended 30 September (unaudited)		
	2021 HK\$'000	2020 HK\$'000	Change	2021 HK\$'000	2020 HK\$'000	Change	2021 HK\$'000	2020 HK\$'000	Change
Respiratory products	110,315	289,943	-62.0%	141,914	303,327	-53.2%	347,005	666,749	-48.0%
Imaging disposable products	46,279	50,084	-7.6%	54,354	51,647	+5.2%	154,602	135,249	+14.3%
Orthopaedic and rehabilitation products	20,012	7,970	+151.1%	21,562	20,229	+6.6%	59,151	41,269	+43.3%
Other products	12,805	23,808	-46.2%	13,532	23,660	-42.8%	41,308	57,942	-28.7%
Total	189,411	371,805	-49.1%	231,362	398,863	-42.0%	602,066	901,209	-33.2%

The above information was prepared based on the unaudited consolidated management accounts of the Group, which have neither been reviewed nor audited by the auditor of the Company, and may differ from those in the audited or unaudited financial statements of the Group to be published by the Company on yearly and half-yearly basis due to various uncertainties during the process of collating such sales information.

Shareholders and potential investors of the Company are advised not to place reliance on the aforesaid information and they are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Vincent Medical Holdings Limited
Choi Man Shing
Chairman and Executive Director

Hong Kong, 21 October 2021

As at the date of this announcement, the Board comprises Mr. Choi Man Shing, Mr. To Ki Cheung, Mr. Koh Ming Fai and Mr. Fu Kwok Fu as executive Directors, Mr. Guo Pengcheng as a non-executive Director, and Mr. Mok Kwok Cheung Rupert, Mr. Au Yu Chiu Steven and Prof. Yung Kai Leung as independent non-executive Directors.